Related Experiment Video

Updated: Dec 29, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.3K

SUMO pathway inhibition targets an aggressive pancreatic cancer subtype

Alexander Biederstädt1, Zonera Hassan2, Christian Schneeweis2

  • 1Medical Clinic and Policlinic III, Klinikum rechts der Isar, Technical University Munich, München, Germany.

Gut
|February 1, 2020
PubMed
Abstract

Insights

Targeting MYC-driven pancreatic ductal adenocarcinoma (PDAC) is crucial. This study links MYC to the SUMOylation pathway, identifying a potential therapeutic vulnerability in aggressive PDAC subtypes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with limited treatment options for resistant subtypes.
  • Genomic MYC amplifications define an aggressive PDAC subset with unique biological dependencies.
  • Understanding MYC-associated dependencies is key to developing novel therapeutic strategies.

Purpose of the Study:

  • To identify and target dependencies associated with MYC hyperactivation in PDAC.
  • To investigate the role of the SUMOylation pathway in MYC-driven PDAC.
  • To evaluate the therapeutic potential of SUMO inhibition in aggressive PDAC.

Main Methods:

  • Analysis of human PDAC gene expression datasets.
  • Immunohistochemical analysis of the SUMO pathway in a large PDAC cohort.
  • Characterization of a SUMO inhibitor in 2D, organoid, and in vivo PDAC models.

Main Results:

  • MYC is intricately linked to the SUMOylation machinery in PDAC.
  • SUMO pathway components are indicative of a PDAC subtype with a poor prognosis.
  • MYC hyperactivation correlates with increased sensitivity to pharmacological SUMO inhibition.

Conclusions:

  • The SUMOylation pathway represents a critical dependency in MYC-amplified PDAC.
  • Pharmacological inhibition of SUMOylation shows promise for treating aggressive PDAC subtypes.
  • Further development of SUMO inhibitor-based therapies is warranted for this PDAC subset.
Keywords:
cancerpancreatic cancer

More Related Videos

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

3.6K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.2K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K